Indacaterol maleate [753498-25-8]
Référence NB-64-03750-10mg
Conditionnement : 10mg
Marque : Neo Biotech
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Indacaterol maleate (Synonyms: QAB149)
Catalog No. T1239 Copy Product Info
Purity: 99.67%
Indacaterol maleate (QAB149) is an ultra-long-acting β-adrenoceptor agonist.
Indacaterol maleate
Copy Product InfoSynonyms QAB149
Indacaterol maleate (QAB149) is an ultra-long-acting β-adrenoceptor agonist.
Cas No. 753498-25-8
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Indacaterol maleate (QAB149) is an ultra-long-acting β-adrenoceptor agonist. |
| Targets&IC50 | β1-adrenoceptor:7.36(pKi), β2-adrenoceptor:5.48(pKi) |
| In vitro | Indacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human β2 adrenoceptors with pEC50 of 8.06. Indacaterol inhibits electrically induced contraction on the electrically stimulated guinea pig trachea in a concentration-dependent manner with pEC50 of 8.23. Indacaterol induces a concentration-dependent inotropic effect with maximal efficacy of 75% in the isolated guinea pig left atrium. [1] Indacaterol reverses the carbachol-induced contraction in a concentration-dependent manner with IC50 of 37 nM in human small airways. Indacaterol concentration dependently reverses the serotonin-induced contraction with IC50 of 10.5 nM in rat small airways. Indacaterol has the highest intrinsic efficacy of 53% in rat small airways and 73% in human small airways. [2] Indacaterol (10 μM) induces close to full inhibition of the EFS-induced contraction of isolated human bronchi and the effect lasts 12 hours. [3] Indacaterol inhibits the IgE-dependent release of histamine from mast cells with the intrinsic activity (Emax of a long-acting Indacaterol/Emax of Isoprenaline) of 1.03. [4] Indacaterol inihbits cAMP release from human airway smooth muscle with pEC50 of 8.53 and Emax of 48%. Indacaterol appears to have a reduced efficacy compared with the CHO-K1 data in the primary ASM cells. [5] |
| In vivo | Indacaterol (6.7 μg/kg) inhibits 5-HT-induced bronchoconstriction with a maximal effect of 85% in the conscious guinea pig. Indacaterol (12.5 μg/kg) dose-dependently inhibits methacholine-induced bronchoconstriction with a maximal effect of 85% in the anesthetized rhesus monkey. [1] |
| Synonyms | QAB149 |
| Molecular Weight | 508.56 |
| Formula | C28H32N2O7 |
| Cas No. | 753498-25-8 |
| Smiles | OC(=O)\C=C/C(O)=O.CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |
| Relative Density. | no data available |
| Storage | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (491.58 mM), Sonication is recommended.  Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.93 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Vous serez peut-être également intéressé par les produits suivants :
Référence
Description
Cond.
Prix HT